Article citationsMore >>

Roop P, Angmo D, Kamble N, Tomar AS. Uncontrolled neovascular glaucoma - an alarming manifestation of chronic mye loid leukemia on imatinib therapy - a case report and review of literature. Indian J Ophthalmol. 2019; 67(2): 285-287.

has been cited by the following article:

Article

Imatinib Related Toxic Optic Neuropathy: Case Report

1Senior Consultant, Pediatric Ophthalmology, Strabismus and Neuro-ophthalmology Service, Centre for Sight, Delhi, India. Pin Code:110029


Neuro-Ophthalmology & Visual Neuroscience. 2021, Vol. 6 No. 1, 4-7
DOI: 10.12691/novn-6-1-2
Copyright © 2021 Science and Education Publishing

Cite this paper:
Monga S. Imatinib Related Toxic Optic Neuropathy: Case Report. Neuro-Ophthalmology & Visual Neuroscience. 2021; 6(1):4-7. doi: 10.12691/novn-6-1-2.

Correspondence to: Monga  S, Senior Consultant, Pediatric Ophthalmology, Strabismus and Neuro-ophthalmology Service, Centre for Sight, Delhi, India. Pin Code:110029. Email: drsumitmonga@gmail.com

Abstract

Imatinib mesylate is a chemotherapy medication. With its use, reversible serious ocular side effects, such as optic neuropathy, retinal edema, etc. have been rarely reported. We report two contrasting presentations of imatinib induced bilateral optic neuropathy. In one case, early diagnosis and withdrawal of the drug averted significant visual loss; while in the other case, advanced bilateral optic atrophy ensued due to the late presentation. To conclude, sight threatening optic neuropathy in patients on imatinib therapy, is a possibility. It may not be necessarily reversible and warrants early discontinuation of imatinib.

Keywords